GoodRx/$GDRX
1D1W1MYTD1Y5YMAX
Capital at risk
About GoodRx
GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.
- Ticker
- $GDRX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 697
- Headquarters
- Santa Monica, United States
- Website
- www.goodrx.com
GoodRx Metrics
BasicAdvanced
$1.2B
71.21
$0.05
1.58
-
Price and volume
Market cap
$1.2B
Beta
1.58
52-week high
$5.81
52-week low
$1.77
Average daily volume
1.5M
Financial strength
Current ratio
1.381
Quick ratio
0.423
Long term debt to equity
0.816
Total debt to equity
0.832
Interest coverage (TTM)
2.19%
Profitability
EBITDA (TTM)
108.776
Gross margin (TTM)
90.83%
Net profit margin (TTM)
2.07%
Operating margin (TTM)
11.36%
Effective tax rate (TTM)
60.75%
Revenue per employee (TTM)
$1,130,000
Management effectiveness
Return on assets (TTM)
3.05%
Return on equity (TTM)
2.52%
Valuation
Price to earnings (TTM)
71.209
Price to revenue (TTM)
1.474
Price to book
1.78
Price to tangible book (TTM)
61.43
Price to free cash flow (TTM)
8.786
Free cash flow yield (TTM)
11.38%
Free cash flow per share (TTM)
0.385
Growth
Revenue change (TTM)
-1.83%
Earnings per share change (TTM)
-46.78%
3-year revenue growth (CAGR)
1.76%
3-year earnings per share growth (CAGR)
32.84%
What the Analysts think about GoodRx
Analyst ratings (Buy, Hold, Sell) for GoodRx stock.
Analyst projections of the future price of GoodRx stock.
Bulls say / Bears say
GoodRx Q2 revenue of $200.4M beat consensus of $193.2M, indicating resilience in its core business. (Investing.com)
Pharma Direct and subscription revenue rose 76% and 39% YoY to $61.6M and $28.5M, demonstrating successful execution of its higher-margin revenue diversification strategy. (SEC Press Release)
Company raised full-year 2026 revenue guidance to $790M-$805M and adjusted EBITDA guidance to $240M-$250M, signaling management’s confidence in sustaining growth. (Investing.com)
Total revenue declined 1% YoY to $200.4M, marking a contraction in overall sales. (SEC Press Release)
Prescription transactions revenue fell 26% YoY to $106.4M due to a drop in monthly active consumers, suggesting challenges in its legacy segment. (SEC Press Release)
Monthly active consumers fell 12% YoY to 5M, indicating shrinking user engagement in its core platform. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 28 Aug 2026.
GoodRx Financial Performance
Revenues and expenses
GoodRx Earnings Performance
Company profitability
Upcoming events
No upcoming events
GoodRx News
AllArticlesVideos
Funds containing GoodRx
AllEURUSDGBP
Fund name | Fund size | $GDRX weighting |
|---|---|---|
SPDR MSCI All Country World IM€SPYI | €7.5B | 0.00% |
iShares MSCI World Small Cap$WSML | $9B | 0.00% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.00% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.00% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.